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Abstract
Hypertrophic cranial pachymeningitis (HCP) is an uncommon dis-
order characterized by localized or diffuse thickening of the dura 
mater, and it usually presents with multiple cranial neurophaties. 
It has been associated with a variety of inflammatory, infectious, 
traumatic, toxic and neoplasic diseases, when no specific cause is 
found the process is called idiopathic. The infectious cases occur 
in patients under systemic immunosuppression, which have an evi-
dent contiguous source or those who have undergone neurosurgical 
procedures. We describe a case of a 62-year-old immunosuppressed 
woman with diabetes and rheumatoid arthritis, which had HCP and 
osteomyelitis of the skull base caused by pseudomonas aeruginosa, 
presenting with headache and diplopia. We believe this is the sec-
ond documented case of pachymeningitis secondary to this micro-
organism. As a multifactorial disease, it is essencial to determine 
the specific causative agent of HCP before making treatment deci-
sions, and great care is needed with immunocompromised patients.
Keywords:  Pseudomonas  aeruginosa;  Hypertrophic  pachymen-
ingitis; Ophtalmoplegia, optical neuropathy; Osteomyelitis; Skull 
base
Introduction
Hipertrophic cranial pachymeningitis (HCP) is a rare clini-
cal entity that is characterized by difuse or localized chronic 
inflammation and hypertrophy of the dura mater [1, 2]. Re-
cently, there has been an increasing number of HCP reported, 
probably because of improvements in imaging studies [3]. 
Several etiologies of HCP have been reported: infectious 
(bacterial, fungal or viral infections), traumatic, toxic, neo-
plasic  and  inflammatory  (rheumatoid  arthritis,  wegener’s 
granulomatosis, sarcoidosis) [4-6]. Most of the infectious 
cases occur in patients under systemic immunosuppression, 
which have an evident contiguous source or those who have 
undergone neurosurgical procedures [7]. In some cases of 
HCP, even after an extensive investigation, no specific cause 
is found, and the process is called idiopathic hypertrophic 
pachymeningitis or primary pachymeningitis [8]. 
At the onset of the disease, most of the patients have 
chronic headache, associated or not with other neurologic 
manifestations such as cranial nerve palsies (such as oph-
thalmoplegia, hypoacusia, disphagia), cerebellar ataxia and 
neuro-ophtamic  complications,  which  include  optic  neu-
ropathy and even blindness [2, 3, 9]. Cranial gadolinium 
magnetic resonance imaging (MRI) is more sensitive than 
enhanced computerized tomography (CT) in demonstrating 
the dura mater thickening. When there is clinical deteriora-
tion or worsening of the neuroimaging despite treatement, 
a dural biopsy is recommended. The biopsy usually shows 
dural hypertrophy and chronic inflammation [6]. 
Skull base ostemyelitis (SBO) typically arises as a com-
plication of malignant external otitis in older male diabetic 
or  immunocompromised  patients,  and  has  Pseudomonas 
aeruginosa as the usual pathogen [10, 11]. Less frequently, 
skull base osteomyelitis can arise from paranasal sinuses in-
fections or odontic caries [11, 12]; hematogenously spread 
osteomyelitis is rare in adults [13]. 
There is only one documented case of HCP and SBO 
secondary to Pseudomonas aeruginosa in the literature [7]. 
As far as we know, our case is the second documented case.
Case Report
A 62-year-old woman was admitted to our hospital in late 
August 2010 with headache and visual complaints which 
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started 2 weeks before. 
She  had  a  history  of  rheumatoid  arthritis  (RA)  since 
1991,  diabetes  mellitus  related  to  chronic  corticosteroid 
therapy since 1995, diabetic retinopathy and chronic venous 
insufficiency with leg ulceration. She was under chronic cor-
ticosteroid therapy (10 mg prednisolone per day for the last 
year) and insulin therapy. During 2010, she was hospitalized 
twice due to septic shock related to infected leg ulcers, the 
first of which in May and the second in July. On both oc-
casions a multi-sensitive Pseudomonas aeruginosa was de-
tected in blood cultures and in the wound exudates. On both 
occasions she was treated with adequate antibiotherapy and 
had a favorable outcome, with clinical improvement. The 
blood cultures became sterile on both occasions, two weeks 
after starting antibiotherapy. After first hospital discharge in 
June, she remained assymptomatic until 1 week before the 
second hospitalization, in July. She was then discharged in 
August, after clinical improvement and with sterile blood 
cultures.
A month after the last hospital discharge, she was admit-
ted to our hospital with a 10 day history of an increasing 
left  fronto-orbitary  headache  and  horizontal  diplopia;  she 
developed complete left eyelid ptosis a few days before ad-
mission. Neurological examination revealed proptosis of the 
orbit, extraocular ophtalmoplegia (III and IV cranial nerves 
palsies) and total central amaurosis, all on the left side. She 
had  no  other  neurologic  deficits.  Laboratory  values  were 
as follows: white blood cells 12.68 × 109 /L (normal range 
4.3 - 10.8 × 109/L) with neutrophil  predominance, hemo-
globin 11.3 g/dL (normal range 12 - 16 g/dL), erythrocyte 
sedimentation  rate  (ESR)  88  mm/h  (normal  range  <  10 
mm/h), C-reactive protein (CRP) 155 mg/L (normal range 
< 10 mg/L), angiotensin converting enzyme (ACE) 11 µg/L 
(normal range 8 - 76 µg/L). The brain MRI (Fig. 1) showed 
pachymeningeal thickening of the anterior and part of the 
middle cranial fossa on the left, specially around the anterior 
clinoid process and the remaining lesser wing of the sphe-
noid; this thickening extended to the orbitary apex through 
the left optic foramen and superior orbital fissure, affect-
ing the extraocular orbitary muscles, compressing the optic 
nerve and infiltrating the bone marrow of the lesser wing of 
the sphenoid and the orbitary wall; this lesion was hypoin-
tense on both T1- and T2-weighted images and proeminently 
enhanced after administration of gadolinium (Fig. 1). The 
paranasal sinuses were empty on CT scan. Lumbar puncture 
showed a clear cerebrospinal fluid (CSF), with normal cell 
count and biochemical parameters; CSF cultures for bacte-
ria were negative; Enterovirus, Cytomegalovirus, Epstein - 
Barr, Herpes 6, Herpes simplex 1 and 2 and Varicella-zoster 
PCR (polymerase chain reaction) testing were negative, as 
were the Cryptococcus count, serologies and immunologic 
tests. Blood cultures were sterile. Mantoux screening test 
and quantiferon (IGRA - interferon-γ release assay) were 
negative. Immunophenotyping of the peripheral blood was 
normal. The immunologic study showed increased rheuma-
toid factor (551 UI/mL) and anti-CCP antibodies (1471 U/
mL), which were similar to previous known results. The oto-
logical exam and orthodontic examination were normal.
Considering the clinical picture, the diagnostic tests and 
the patient’s known diseases, the possibility of an inflamma-
tory or granulomatous lesion was placed.  The patient was 
treated with a high dose of intravenous methylprednisolone 
(1g per day during 5 days), followed by 40 mg of prednis-
olone per day (tapering after 1 week), but she got worse, 
developing right eyelid ptosis and total bilateral amaurosis; 
the MRI showed no change. The bad clinical response to the 
high-dose  of  corticosteroid  and  the  immunocompromised 
state of the patient raised suspition of a fungal or bacterial 
infection,  so  we  started  amphotericin  B  plus  ceftazidime 
(this antibiotic was started because of the suspicion of an 
infection caused by Pseudomonas aeruginosa, based on the 
previous blood cultures of the patient). 
A brain biopsy was scheduled and it showed a thickened 
dura mater, chronic non-granulomatous inflammation com-
Figure 1. (a-c) MRI images (coronal and horizontal cuts) showing a pachymeningeal thickening around the left anterior clinoid pro-
cess and lesser wing of the sphenoid, that extends to the left anterior cranial fossa and the anterior part of the middle cranial fossa; it 
also extends to the orbitary apex through the left optic foramen and superior orbital fissure, affecting the extraocular orbitary muscles, 
compressing the optic nerve and infiltrating the bone marrow of the lesser wing of the sphenoid and the orbitary wall. This lesion was 
hypointense on both T1- and T2-weighted images and proeminently enhanced after administration of gadolinium.
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patible with osteomyelitis and tissue predominance of gram 
negative  bacteria,  identifyed  as  Pseudomonas  aeruginosa, 
similar to the one identified on both blood cultures performed 
a few months before. We stopped amphotericin B and kept 
ceftazidime (2 g every 8 hours), according to the bacteria 
sensitivity. As osteomyelitis was present, we decided to do a 
12-week course of antibiotherapy during hospital stay, with 
good clinical response. The headache only improved with 
opioids. There was an improvement of the ocular and eyelid 
movements, but her vision did not improve, so that she main-
tained total bilateral amaurosis, despite the antibiotherapy. 
Visual evoked potentials showed a serious compromise of 
the  pre-chiasmatic  component,  probably  irreversible.  Be-
yond the neurologic deficits, she showed clinical improve-
ment, with no other clinical problem.
In  spite  of  this  clinical  improvement,  the  MRI  per-
formed at the end of the 12 weeks revealed the same lesion, 
now with partial occlusion of the internal carotid artery. The 
whole-body FDG-PET (fluorodeoxyglucose-positron emis-
sion tomography) showed no hypermetabolic activity in the 
brain, which led us to interpret the MRI lesion as fibrosis. 
During her hospital stay we provided occupational ther-
apy to begin her adaptation to her new life. 
When the patient was discharged she was asymptomatic; 
she was under prednisolone 10 mg per day. After discharge, 
she was followed in regular medical consultations, and two 
months after hospital discharge she maintained the previous-
ly described neurological deficits, otherwise asymptomatic, 
with no signs of infectious relapse.
Discussion
  
HCP refers to a well-circumscribed area of chronic inflam-
matory dura thickening, but all three meningeal layers be-
come fused by dense fibrotic membranes [7]. There is no 
sex or age predominance [14]. Patients usually present with 
multiple  progressive  cranial  neuropathies  [5];  the  clinical 
features appear to be associated with the location of the ab-
normal dura mater observed on gadolinium MRI [6]. The 
optic nerve is the most frequently affected [5], and when it 
is envolved, the visual prognosis is poor [15]. MRI imag-
ing tipically reveals well-circumscribed hyperintense lami-
nar thickening of the dura, with low T2 signal intensity and 
enhancement after intravenous infusion of gadolinium or a 
similar agent [16, 17]. 
HCP may be primary or idiophatic when no cause is 
found,  or  secondary  when  identifiable  causes  exist  [18]. 
The most frequent causes of secondary HCP are infectious; 
syphilis and tuberculosis are the most frequently reported, 
mainly in developing countries or in immunocompromised 
patients [19]. Other pathogens such as Candida, Aspergillus, 
Pseudomonas or any other that cause infection of the extra 
or subdural space, paranasal sinuses or mastoid, can induce 
thickening of the dura mater [20-23]. Non-infectious causes 
of secondary HCP include traumatic, inflammatory (sarcoid-
osis, rheumatoid arthritis, Wegener’s granulomatosis, poliar-
treitis nodosa, among others) and toxic causes [4, 7, 14]. 
HCP presents with symptoms that can mimic other dis-
eases, such as subdural hematoma [24, 25] or dural carci-
nomatosis [26], so that some imagiologic exams have to be 
done to exclude those clinical entities. 
This rare disorder is a diagnosis of exclusion, because 
its appearance on MRI is often similar to other diseases as 
meningioma  en  plaque,  lymphoma,  tuberculosis  and  sar-
coidosis; when the systemic workup is nondiagnostic, cra-
niotomy with meningeal biopsy is required to differenciate 
between those diseases [7, 17]. When we have a typical im-
age on the MRI and typical histologic findings, we should 
seek the cause of HCP, if not found, it´s called idiopathic 
HCP or primary HCP; idiopathic HCP is always a diagnosis 
of exclusion [14, 27]. 
The first case of pachymeningitis was reported in 1869 
by Charcot and Joffroy [28]; since then, there have been sev-
eral cases reported, secondary to a variety of causes, how-
ever, most cases remain idiopathic [9, 26]. 
Most of the cases of infectious HCP are related to bacte-
rial sphenoid and ethmoid sinusitis and chronic otitis media 
[29, 30]; the hematogeneous spread of infections is not com-
mon in HCP, and there are no cases described on the litera-
ture. On the other hand, most of the cases of skull base osteo-
myelitis originate in malignant external otitis, less frequently 
in paranasal sinusitis and rarely from hematogeneous spread 
[31, 32]. 
In this case, our patient had HCP and osteomyelitis of 
the skull base, probably caused by Pseudomonas aerugi-
nosa, the only isolated bacteria. Before the results of the bi-
opsy, the bad initial response to corticotherapy was a clue to 
an infectious cause, either fungal or bacterial; furthermore, 
our patient was diabetic and immunocompromised due to 
chronic  corticotherapy,  which  implies  greater  susceptibil-
ity to infections. In addition to the suggestive findings of 
HCP and osteomyelitis on the MRI, her clinical picture was 
typical and the biopsy findings strongly suggested those di-
agnostics. Initially there was no clear route of entry for the 
microorganism; we did an extensive imagiologic and clini-
cal evaluation for a contiguous source, but there was no evi-
dence of infeccious sinusitis, external or media otitis or other 
kind of contiguous infection. Pseudomonas aeruginosa was 
the only bacteria identified in the biopsy specimen and in the 
cultured tissue sample, similar to the one identified on both 
blood cultures performed a few months before; we assumed 
therefore that our patient had hipertrophic cranial pachymen-
ingitis and skull base osteomyelitis caused by Pseudomonas 
aeruginosa, which probably resulted from a hematogenous 
spread.
According to the literature, meningitis caused by Pseu-
domonas aeruginosa is rare [33], and it’s more common in 
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immunocompromised patients, who have undergone neuros-
surgical procedures [34] or who have chronic otitis media 
[35]. Skull base osteomyelitis caused by Pseudomonas aeru-
ginosa is generally caused by malignant external otitis, and 
it has also been described as arising from infection f the pa-
ranasal sinuses and from mandible or maxilla due to odontic 
caries [36, 37]. Taking into account that our patient had two 
previous episodes of bacteriemia (from infected venous ul-
cers of the leg) due to the same strain of Pseudomonas aeru-
ginosa found in the brain biopsy, this was the more obvious 
route of entry for the infection, although rare. As far as we 
know, this is the second case of Pseudomonas aeruginosa 
HCP and skull base osteomyelitis described in the literature; 
the first one was an immunocompetent 60-year-old man, de-
scribed by Girkin CA et al in 1998 [7].
Our  patient  neurologic  deficits  improved  with  the 
12-weeks course of ceftazidime, in spite of the persistent 
bilateral amaurosis, which was probably due to irreversible 
optic nerve destruction. The overall good response to anti-
biotherapy helped to confirm the infectious etiology of this 
HCP. Infectious cases are not well reported in the literature, 
but there is a high mortality risk; a high index of suspicion 
may be life saving. Involvement of the optic nerve usually 
confers a poor visual prognosis. Antimicrobial therapy may 
show some visual improvement in the infectious cases; in 
non-infectious cases some improvement in visual acuity has 
been shown with high dose corticosteroid treatment [38]. 
Some cases recover after surgical removal, but the disease 
progression  is  always  uncertain,  and  relapses  may  occur 
[26]. 
Cranial  gadolinium  MRI  is  more  sensitive  than  con-
trast enhanced CT in demonstrating the thickened abnormal 
enhancing dura-mater; non-contrast CT should be used to 
exclude neoplasia [39]. The definitive diagnosis is made by 
histophatological findings, which usually show an inflam-
matory  process  with  lymphomononuclear  cell  infiltration 
and a thickened dura-mater characterized by a dense hypo-
cellular fibrous tissue [1, 40]. In relation to the follow-up of 
the disease there is no stablished consensus. On this particu-
lar case, we had a persistent pachymeningeal thickening on 
the MRI, which did not improve after the 12-week course 
of antibiotherapy; the clinical improvement of the patient 
and the absence of hypermethabolic lesions on the PET scan 
were the facts that led us to consider that the infectious/in-
flammatory lesion was improving. There are some studies 
showing the role of gallium-67 scintigraphy and FDG-PET 
on the follow-up and detection of relapse of HCP, not pos-
sible with the MRI [41-43]. Various nuclear medicine im-
aging techniques have been advocated in suspected SBO, 
including gallium-67 scintigraphy, white blood cell scans, 
technetium-99 bone scans, and PET (positron emission tech-
nique) scans [12, 44]. The latter two techniques may have an 
advantage over CT and MRI in revealing persistent osteo-
myelitis and may be more useful in the follow-up of patients 
under antibiotics, because marrow signal change may persist 
for up to 6 months after successful treatment. There is cur-
rently no imaging technique to replace the role of biopsy for 
microbiological culture in cases of suspected SBO [11, 44]. 
There is also no consensus about the length of treatment 
of HCP and SBO. There is not a minimal time of antibio-
therapy advised in the case of infectious HCP. The length of 
antibiotherapy in SBO is variable among the cases reported, 
but globally treatment was given for at least 1 month and up 
to 6 months [11, 12, 44]. Adjuvant hyperbaric oxygen may 
also provide benefit [12, 44]. We decided to do a 12-week 
course of antibiotherapy to treat our patient, having into ac-
count the improvement of the symptoms and the imaging 
findings in the PET scan.
Most of cases of HCP are idiopathic, and they have a 
good response to steroids [45, 46]. Most of the patients treat-
ed with them show improvement and stabilization, which 
gives a clue about the inflammatory nature of most of these 
lesions [46, 47]. In some cases, due to the need of large doses 
of corticosteroids, these patients are also treated with immu-
nomodulators, like methotrexate or azathioprine [26, 48-50]. 
Non-idiophatic HCP, like infectious or malignant conditions, 
is not responsive to corticosteroids but are usually respon-
sive to specific therapies, as antibiotics or radiotherapy [51]. 
The surgical treatment is rarely used in HCP, although sur-
gical optic channel decompression [45, 48] and ventriculo-
peritoneal derivation [52] are sometimes necessary in cases 
of obstructive hydrocephaly. 
Due to the extensive differential diagnosis of this clini-
cal entity, the evaluation of HCP requires blood and cere-
brospinal fluid (CSF) evaluation, contrast MRI, a physical 
examination and in most cases a dura mater biopsy. Serum 
angiotensin converting enzyme, c and p-ANCA, rheumatoid 
factor and anti-nuclear antibody must be tested; an evalua-
tion of Lyme, syphilis, tuberculosis and fungi is also neces-
sary [8, 14]. The CSF findings are dependent on the etiology; 
when infection is not present, CSF frequently shows non-
specific pleocytosis, predominantly lymphocytic; there may 
be an increase in protein content [39, 51]. 
Systemic autoimmune and rheumatologic diseases that 
can present with similar clinical and radiologic features must 
be considered in the evaluation of HCP; for example, pa-
tients with RA sometimes develop headache and optic neu-
ropathy with fibrosis and chronic inflammatory infiltrate of 
the dura-mater [53, 54]. In our patient´s case, she had RA 
and had a chronic inflammatory infiltrate of the dura-mater, 
but it was proved to be infectious at the end; as she was an 
immunocompromised  patient,  the  infectious  cause  should 
have been considered since the beginning.
Biopsy of the dural lesion should be considered and it’s 
recommended when the patient clinically deteriorates or the 
neuroimaging worsens despite treatment; it’s a low risk pro-
cedure, and it’s considered the gold-standard for the diagno-
sis [48, 52]. Chronic inflammation of the usually inert dura-
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mater with minimal or no inflammation of pia and arachnoid 
should be seen in HCP [6, 48]. 
The  natural  course  of  this  disease  isn´t  completely 
known. HCP frequently progresses if untreated; the idiopath-
ic cases treated with corticosteroids usually improve, but that 
benefit may be temporary and partial [9, 55]. In some cases 
there is a subclinical progression of the disease despite long-
term treatment [55]. The optic neuropathy usually improves 
or stabilizes; the majority of patients with visual loss main-
tain their vision because it is usually secondary to inflamma-
tion rather than compressive fibrosis around the optic nerve 
[6]. Our patient had permanent visual loss, probably due to 
compressive fibrosis, as described above. 
Oclusion of the intracranial vessels by the inflammatory 
mass is a frequent complication of HCP, namely the internal 
carotid artery and dural sinuses [48, 56]. It happened on our 
case, but apparently our patient remained clinically stable, 
with no new neurologic deficits.
There are some authors that speculate that inflamma-
tory myofibroblasyic tumor (IMT), Tolosa-Hunt syndrome 
(THS) and idiopathic HCP may be various presentations of 
a spectrum of inflammatory disorders that have diverse loca-
tions but share similar histologic, clinical and imaging find-
ings [57, 58]. IMT is also known as “myofibroblastoma” or 
“inflammatory pseudotumor”, and is characterized by prolif-
eration of myofibroblastic spindle cells with mixed inflam-
matory infiltrates of plasma cells [59]; IMTs often include 
orbital involvement [60]. THS is a retro-orbital pseudotumor 
that  involves  the  cavernous  sinus,  with  imaging  findings 
similar to IMT [39, 58]; it causes a painfull oftalmoplegia 
due to a nonspecific granulomatous inflammation of the cav-
ernous sinus. Some described cases of THS have concurrent 
pachymeningitis in other portions of the cranial vault, rais-
ing the possibility that THS may be a focal manifestation of 
idiopathic HCP [61]. On the other hand, there are cases of 
idiopathic HCP with a simultaneous orbital mass [62]. The 
main clinical features of these 3 disorders include headache 
and cranial polyneuropathy, usually leading to visual symp-
toms [57, 61]; they all typically respond to steroid therapy 
[61]. This reinforces the idea that these clinical entities may 
somehow be related and may possibly be different presenta-
tions of the same disease [63]. This comparison can only be 
made between IMT, THS and idiopathic HCP, since infec-
tious HCP is a different entity and needs another clinical ap-
proach, as was the case of our patient.
In conclusion, HCP is a unique clinical entity character-
ized by fibrosis and thickening of the dura mater and variable 
neurological disfunction. However, there is a wide variety 
of causes of HCP – infectious, granulomatous, neoplasic, 
and inflammatory. There are even authors that argue that this 
is not a single disease but a wide variety of diseases with 
similar  clinical  expression  but  with  different  therapeutic 
approach. There is no consensus on the literature about the 
most adequate treatment of this disease, probably because 
of the wide variety of diseases we are talking about and the 
rarity of the disease.
Before making decisions about the most adequate treat-
ment, it’s essencial to determine the specific etiology of the 
HCP; corticosteroids must be used carefully, mainly in pa-
tients with history of tuberculosis or the immunocompro-
mised, as we had in the case described; infectious causes 
must always be excluded. On this particular case, with the 
known history of bacteriemia due to Pseudomonas aerugi-
nosa, the hipotesis of infectious HCP should have been put 
sooner. In fact, it seems that an adequate and prompt treat-
ment of HCP is the main key of the therapeuthic success of 
these patients.
There is still a lot to clarify about this subject in the lit-
erature. There is a lack of complete follow-up throughout the 
progress of the disease; there are only sporadic cases, and 
the majority is labeled as idiopathic. A lot of studies are still 
needed to understand this clinical entity.
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